Canadian Enrollment Begins in B-SILENT Study of Sonorous’s BosStent Cerebral Venous Stent

September 2, 2026—Sonorous Neurovascular announced the commencement of enrollment at Canadian sites in the B-SILENT clinical study of the company’s investigational BosStent.

TRUST Pivotal Study of Innova Laguna Thrombectomy System Completes Enrollment

September 1, 2026—Innova Vascular, Inc. announced the completion of patient enrollment in the TRUST pivotal investigational device exemption clinical study, which is evaluating the safety and effectiveness of the company’s Laguna thrombectomy system for the treatment of pulmonary embolism (PE).

FDA Clears ThinkSono’s Ultrasound AI Guidance Software to Evaluate Suspected DVT

July 29, 2026—ThinkSono announced that the company’s ThinkSono Guidance software has received FDA 510(k) clearance that provides real-time guidance to nonultrasound-trained health care professionals during the acquisition of vascular ultrasound images.

The PERT Consortium CEO Michelle Lanno to Step Down at Year’s End

July 20, 2026—Michelle Lanno, Chief Executive Officer of The PERT Consortium, announced she will be stepping down from her role effective December 31, concluding more than a decade of leadership that began with the organization’s founding in 2015.

SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

Ventiv Scientific’s V-Pulse Mechanical Thrombectomy System Used in FIH Procedures 

June 11, 2026—Ventiv Scientific announced the completion of the first-in-human (FIH) clinical procedures with its V-Pulse mechanical thrombectomy system.

Gore Viabahn Fortegra Venous Stent Receives CE Mark Approval Under EU MDR

June 9, 2026—Gore & Associates announced CE Mark approval for its Viabahn Fortegra venous stent, indicated for use in the treatment of symptomatic inferior vena cava (IVC) and iliofemoral venous outflow obstruction. The approval is granted under the European Union Medical Device Regulation.

ENGULF Analysis Shows Reduced Blood Loss With E2’s Hēlo System in PE Procedures

May 4, 2026—A comparative analysis from the ENGULF trial demonstrated that using blood return during continuous aspiration thrombectomy dramatically reduced blood loss by 97%, while maintaining hemodynamic efficacy and improving procedural efficiency.

FDA Awards IDE for Pivotal Study of enVVeno’s Venous Valve to Treat Severe Deep CVI

May 1, 2026—enVVeno Medical Corporation announced it has received an FDA investigational device exemption (IDE) for the pivotal study of the company’s enVVe transcatheter venous valve endoprosthesis (TAVVE) in the United States.

BD Launches CentroVena One Insertion System

April 29, 2026—BD (Becton, Dickinson and Company) announced the commercial launch of the BD CentroVena One insertion system, which is an all-in-one central venous catheter (CVC) insertion device.

Pain and QoL Data Presented for Gore’s Viabahn Fortegra Venous Stent

April 22, 2026—Gore & Associates announced new 12-month findings from the global GORE VIABAHN FORTEGRA Venous Stent IVC trial, which evaluated treatment of patients with symptomatic deep venous iliocaval obstruction.

Sonorous BosCath Neurovascular Catheter Cleared by FDA

April 22, 2026—Sonorous Neurovascular, a developer of solutions for cerebral venous diseases and neurovascular interventions, announced that it has received FDA 510(k) clearance for its BosCath, allowing the company to commercialize the next-generation neurovascular catheter in the United States.

Data Presented From Pilot Trial of InVera Infusion Device for Chronic Venous Disease 

April 21, 2026—InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of chronic venous disease (CVD).

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

C-TRACT Evaluates Endovascular Therapy to Treat Postthrombotic Syndrome After DVT 

April 13, 2026—The Society of Interventional Radiology (SIR) announced results from the C-TRACT study, which is investigating the treatment of postthrombotic syndrome (PTS) after deep vein thrombosis (DVT).

BD’s Liverty TIPS Stent Graft Receives CE Mark Approval in Europe

April 10, 2026—BD (Becton, Dickinson and Company) announced European CE Mark approval for the Liverty transjugular intrahepatic portosystemic shunt (TIPS) stent graft.

FDA Clears InVera Infusion Device to Treat Chronic Venous Disease

April 8, 2026—InVera Medical announced FDA 510(k) clearance for the InVera infusion device for the minimally invasive treatment of diseased leg veins, including varicose veins.

Embolization, Inc.’s Polymer-Based NED Coil Evaluated in Limited-Market Release 

April 7, 2026—Embolization, Inc. announced findings from the limited-market release of the company’s nitinol enhanced device (NED), which is a radiopaque, polymer-based embolic coil.

Baylis Launches PowerWire 14 RF Guidewire to Treat Arterial and Venous Occlusions

April 7, 2026—Baylis Medical Technologies Inc. announced FDA 510(k) clearance and the commercial launch of the company’s PowerWire 14 radiofrequency (RF) guidewire, which is intended for use in both arterial and venous occlusions.

HI-PEITHO: Boston Scientific’s Ekos System Superior to Anticoagulation Alone in Acute Intermediate-Risk PE

March 28, 2026—Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endovascular system in patients with intermediate-risk pulmonary embolism (PE) met the composite primary endpoint.